Drug Approval | November 12, 2021
Sun Pharma to introduce molnupiravir in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
Biocon Biologics and Viatris co-developed the products
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Subscribe To Our Newsletter & Stay Updated
